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Abstract 
 
Quantitative data on melatonin in stroke patients are scarce. Gender- and age-matched cross-sectional case-
control study in 33 patients with ischaemic stroke (IS) was performed and associations between nocturnal 
melatonin and other factors (e.g., cortisol) evaluated. Clinical and laboratory (e.g., melatonin and cortisol) 
measurements (3 and 8 a.m.) with statistical techniques [e.g., multifactorial regressions, receiver operating 
characteristics (ROC) curve and curvilinear estimations] were used. We identified mean value and 95% 
confidence interval (69.70 pg/ml, 95% CI 53.86-85.54) for control levels of nocturnal melatonin in 
healthy subjects. The patients with stroke had lower melatonin (48.1±35.9 pg/ml) and higher cortisol 
(297.3±157.8 nmol/l) at 3 a.m. (p<0.05) but not at 8 a.m. (p>0.05). The stroke was the strongest factor of 
disturbed nocturnal cortisol (p<0.001) while decreased melatonin depended on the stroke (p=0.010) and 
gender (p=0.018). In the same time, vice versa, only nocturnal measures were associated with increased 
probability of presence of stroke (accuracy>75%, p-model<0.001). Thus, a hypothesis that a decrease of 
melatonin with 1.0 pg/ml might be associated with >2% increase in the probability of presence of stroke 
[adjusted odds ratio = 1.020 (95%CI 1.002-1.037)] was also suggested. ROC curve (0.67, p=0.0119) and 
optimisation techniques indicated that a novel best cut-off<51.5 pg/ml for decreased nocturnal melatonin in 
the view of the presence of stroke (odds ratio = 3.12, p=0.0463) might exist. The classification 
performance of such cut-off might be confirmed by existing nocturnal melatonin and cortisol differences 
between the sub-groups; potential differences in diurnal melatonin were also suggested. In conclusion, a 
novel melatonin cut-off of 51.5 pg/ml may be associated with the presence of ischaemic stroke. As a single 
marker (84% sensitivity, 74% specificity), its hypothesised modelling performance was independent of age, 
gender and cortisol. These new results, including the suggested hypothesis, might be further tested in 
follow-up (cohort), longitudinal studies and be applied to further explore melatonin disturbances as targets 
in high-risk pre-stroke and post-stroke patients.   
 
Key words: Melatonin, Cortisol, Modelling, Acute Ischaemic Stroke, Bulgaria 
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Introduction 
 
Melatonin (N-acetyl-5-methoxytryptamine) was isolated in 1958 by Lerner and collaborators due to its 
ability to aggregate melanin granules in melanocytes, thus, decreasing the pigmentation in reptiles [1]. 
Produced by the pineal gland, melatonin is one of main pacemakers of circadian rhythms in vertebrates, 
including humans. It is a neuro-hormone – its synthesis occurs in a diurnal pattern with a night peak. The 
light-dark cycle is a prominent synchronising factor [2] of the circadian system; e.g., the decrease in 
melatonin in the light might be seen as an acute response that is associated with degradation of 
serotonin N-acetyltransferase (SNAT). The melatonin increases after the onset of darkness, peaks in the 
middle of the night (2-4 a.m.) and gradually decreases. Melatonin rhythm can be interrupted by light which, 
depending on the phase of its application, may provoke disturbances of its circadian cycle. Also, exposure to 
light, independently of phase, suppresses melatonin secretion [3-4]. After its synthesis, melatonin is released 
in blood and liquor of the third cerebral ventricle. 
Earlier studies have shown that melatonin secretion profiles are disturbed in stroke patients. For 
instance, the maximal excretion of 6-sulphatoxymelatonin in urine occurs with a delay [5-7]. This effect is 
specific during the first 3-4 days after stroke where the mean melatonin excretion is lower but these changes 
recover at the tenth days and do not correlate with stroke severity, age or gender [6]. This study indicated 
decreased nocturnal values of melatonin in urine during the acute and chronic phases of stroke that were 
suggested to contribute to neuro-psychological changes in such patients. Of note, relationships were reported 
between the impaired melatonin/cortisol ratio, sleep disturbances and depressive symptoms [7].  
We aimed at exploring that melatonin profile disturbances during the acute phase of ischaemic 
stroke, e.g., a decreased nocturnal melatonin at 3 a.m. (main, primary outcome) is independently 
associated with the presence of stroke. However, since within the framework of our cross-sectional 
design we could not be certain whether such melatonin disturbances (if any) were ex novo or existed 
prior to the ischaemic stroke, we also hypothesized that a possible association might exist (secondary 
outcome) between melatonin profile disturbances and increased probability of ischaemic stroke. Most 
of earlier studies reported various control levels for nocturnal melatonin in healthy subjects.  If true, 
our secondary hypothesis may further indicate an increased probability of ischaemic stroke in patients 
with disturbed melatonin profile, e.g., at previously lower levels of nocturnal melatonin or, so called 
‘hidden’ amplitude or rhythmic disturbances. To note, such stroke-related values were not quantified 
earlier in human subjects. 
To formally test and quantify “stroke-melatonin” association and control for potential confounders 
(e.g., cortisol), we performed cross-sectional, matched case-control study on serum melatonin at two pre-
specified time points (3 a.m., 8 a.m.) in 33 gender- and age-matched patients during the acute phase of 
ischaemic stroke. We evaluated the associations with impaired melatonin in 33 IS patients versus 33 healthy 
controls (33 matched pairs). The results of this modelling approach formed the basis of the present report. 
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Methods 
Patients’ selection 
We studied 33 consecutive ischaemic stroke patients referred during the period Jan–Dec 2006 to the Clinic 
of Cerebrovascular Diseases who satisfied the selection criteria and provided written informed consent 
according to the Declaration of Helsinki guidelines. Inclusion criteria were: age <60 years, occurrence of 
first ischaemic stroke, hospitalization up to 6 hours after the appearance of neurological symptoms and CT-
scan or MRI-confirmed diagnosis of the ischaemic stroke. Exclusion criteria were: haemorrhagic stroke, 
arterial hypertension, traumatic brain injury, neurological infections, renal insufficiency, impaired liver 
function, malignant disease, systemic diseases of connective tissue, and surgical interventions up to 3 months 
prior to the index event (stroke), consciousness disturbances, abstinence reactions and drugs intake up to 3 
months before hospitalization if influencing melatonin. The Ethical Committee approved the study protocol. 
 
Study Design 
Thirty-four patients with ischaemic stroke were identified as cases (n=34). For each case, one healthy subject 
without ischaemic stroke was identified as control (1:1). Identified controls satisfied same inclusion/ 
exclusion criteria (n=34). Cases and controls were matched for gender and age (±5 years). Each case was 
matched with the first control as identified on the basis of above criteria (Figure 1). After identification and 
matching, 2 subjects (1 cases and 1 control) did not provide written informed consent and did not participate 
in the study. Out of 68 identified subjects, 33 cases and 33 controls entered and completed the study. 
 
Clinical and laboratory methods 
Each case and control subject who participated and completed the study underwent an extensive physical and 
laboratory evaluation. All relevant demographic, clinical and laboratory data were reported in case record form.  
Clinical examination: History of the onset of the cerebrovascular accident and its development till the 
hospitalization, physical examination, mental status and neurological examination with assessment of 
neurological deficit (by modified Rankin scale [8].  
Instrumental and neuro-imaging procedures: CT or MRI of the brain, 12-channel ECG, extra- and 
transcranial Doppler sonography for confirmation of ischaemic stroke diagnosis.  
Laboratory tests: The biological material for all routine clinico-laboratory analyses was taken between 
7:00 h and 9:00 h in the morning, unless stated otherwise, following all standard requirements for quality of 
laboratory results during pre-analytical stage. Blood tests (Coulter STKS, USA), coagulation tests 
(prothrombin time, activated partial thromboplastin time and fibrinogen by Sysmex CA 6000, Kobe, Japan), 
tests for serum creatinine and routine biochemical and enzyme parameters (Konelab 60i, Finland).  
a) Melatonin assessment procedure: Blood samples were taken on day 3 from hospitalization, at 
3:00 and 8:00 a.m. The procedure consisted of selecting a separate room for hospitalization with dedicated 
medical personnel. The same therapeutic protocol and regime were applied to all patients. During the 
daytime, the room was illuminated by normal daylight. During night, to ensure complete darkness, the 
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windows were covered by black paper. Artificial light source was switched-off at 22:00 h. For determination 
of melatonin levels, two sampling per patient were performed at specific time point – 3:00 a.m. and 8:00 
a.m., in the morning. Subjects were instructed to keep their eyes closed during blood sampling at 3:00 a.m.  
The blood sampling at 3:00 a.m. was performed at very weak light and with a maximally shortened 
procedure, without illuminating the face of subjects. The blood sampling at 8:00 a.m. was performed under 
normal daylight. The separated serum for determination of melatonin was preserved in conic plastic test-
tubes with cover type Eppendorf at 2-8 degree Celsius for 24 hours or frozen at temperature ≤ -20 degrees 
Celsius for 3 months. Sera with haemolysis, lipaemia or icter were excluded from testing. For determination 
of melatonin, test kit for immunoenzyme assay in serum and plasma (IBL-Hamburg, Germany, cat. number 
RE54021) was applied by concurrent heterogeneous immunoenzyme ELISA-based method (analyzer “Sirio 
S” microplate reader, SEAC, Italy). 
 b) Cortisol assessment procedure: The blood for determination of serum cortisol was provided by 
closed system for biological sampling. The equipment Monovette Sarstedt (cat. numbers 05.1553.001) for 
clinico-chemical analyses was used. The serum was separated from forming elements by blood 
centrifugation (15 min, 3000 rotations/min) by centrifuge with horizontal rotor Т230 Janetzki (Germany). 
The reagents for FPIA (fluorescent-polarization analysis) with test kit (Abbott Laboratories, USA, cat. 
number 9116) were used by analyzer Tdx/FLx (Abbott, reference values: 150-830 nmol/l at 7:00-9:00 a.m.). 
 
Sample size estimation 
The sample size was calculated on the basis of an expected difference in the primary outcome variable (e.g., 
nocturnal melatonin at 3.00 a.m.) between the cases with IS and controls (healthy subjects). We have taken 
as a basis the melatonin profile amplitude of 87 pg/ml and its standard deviation (SD) of 19.4 pg/ml in 8 
normal, healthy subjects during a nocturnal surge of ≈12 hours (10.23 p.m.-10.23 a.m.) with 95% confidence 
interval (CI) 70.8-103.2 pg/ml (variation ≈55-95 pg/ml at about 3-4 a.m., [9]). Assuming the same standard 
deviation of 19.4 (pooled) for IS patients and a minimum average difference of ≈15.5% (>13.5 pg/ml) from 
controls, it was estimated that to give the study a power of 80% to detect such expected difference as 
statistically significant at p<0.05, 32 patients per group had to be included. By a preliminary estimate of IS 
prevalence for patients that would satisfy inclusion/exclusion criteria from all those referred to the Clinic of 
Cerebrovascular Diseases, it was predicted that 68 patients (34 cases and 34 controls) needed for the analyses 
should be identified throughout a screening period of about 12 months (estimated maximum drop-out ≈5%).  
 
Statistical analyses 
The characteristics of the cases and controls were assessed by methods of descriptive statistics and tests of 
normality, and the two groups were compared by two-tailed independent sample Student's t-test, χ2 test or 
non-parametric tests, as appropriate. Prior to the analyses, the variables with skewed distribution were 
normalized by log-transformation. The associations among the main variables listed in Table 1 and the 
ischaemic stroke were evaluated by univariate analyses. Logistic and parametric regression analyses were 
applied by entry and backward stepwise methods with adjustment for covariate effects (logit link function 
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with likelihood ratio or conditional tests, as appropriate) to those variables that were significantly associated 
with the ischaemic stroke at univariate analyses or served as matching criteria. Logistic curve estimation 
function was used to fit the regression models. Receiver operating characteristics (ROC) curve analysis was 
applied to test the models’ internal validity as well as to define the best cut-off values that implied 
discrimination points between the sub-groups of participants with low or high probability for presence of 
ischaemic stroke. Data are mean (±S.D.) or number and frequency (percentage), unless otherwise stated. The 
statistical significance of all tests was assumed at p<0.05, unless stated otherwise. 
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Results 
Patients’ characteristics  
The main demographic, clinical and laboratory features of IS patients included in the present study are given 
in Table 1. As expected, since 33 patients with IS were matched with 33 healthy controls, no differences in 
gender and age distributions were observed (20 males vs. 13 females, 58.4±7.5 vs. 55.3±7.4 years, 
respectively). Only 2 patients in either cohort denied their consent to study participation and were not 
included. Their characteristics were similar to those of included patients (Figure 1).  
 According to the clinical data, the IS diagnosis in 33 patients was most frequent in the region of the 
carotid system (the middle cerebral artery - 72.7 % and the vertebrobasilar system – 27.3%), with subacute 
onset of the neurological deficit being also more frequent. The neurological examination had revealed typical 
abnormalities in the damaged region, e.g., hemipareses, motor/sensor aphasias, etc. Most frequently observed 
neurological impairments, mainly with paresis symptoms, had a Rankin score of 3 (48.4%). More than one-
half of the IS patients had abnormal Doppler sonography findings, while the brain CT scan/MRI indicated 
abnormal findings in 60.6%.  
 
Comparative analyses  
The IS patients and healthy controls were similar not only for the matching variables, but also for melatonin 
and cortisol diurnal (at 8 a.m.) values and normal serum creatinine (Table 1). Patients with IS, however, had 
lower melatonin and higher cortisol nocturnal (at 3 a.m.) levels (p<0.05). Distribution of individual levels 
of melatonin at 3 a.m. is shown for all study participants (Figure 2). We identified a 95% confidence 
interval for a melatonin peak in our healthy subjects to be from 53.86 to 85.54 pg/ml that served as control 
levels for further analyses.  
 Having found a statistically significant difference in the nocturnal levels of melatonin 
(primary, main outcome), we then performed a multifactorial parametric regression (Table 2) which 
revealed that IS was the strongest factor of disturbed nocturnal cortisol (p<0.001). The decrease of nocturnal 
melatonin depended upon the presence of IS (p=0.010) and male gender (p=0.018) as independent factors. 
Because of the cross-sectional nature of our study, vice versa, we further tested our secondary 
hypothesis and found that at backward logistic regression only nocturnal melatonin and cortisol were 
independently associated with increased probability of IS [odds ratio (OR) of 0.30 and 6.22, respectively, 
model accuracy > 75%, pmodel<0.001, Table 3]. A decrease of melatonin with 1.0 pg/ml was associated with 
>2% increase in the probability for the presence of ischaemic stroke [adjusted OR = 1.020 (95%CI 
1.002÷1.037)]. 
 Further, the ROC curve analysis (ROCAUC=0.67, 95CI% 0.54-0.78, p=0.0119) and optimisation 
techniques (Figure 3) indicated a novel best cut-off value <51.5 pg/ml for a decreased nocturnal melatonin 
(at 3 a.m.) in the view of increased probability of IS. An additional analysis of IS patients versus controls, 
by “normal”/”abnormal” nocturnal melatonin profile in 4 sub-groups according to the new cut-off value of 
51.5 pg/ml (i.e., below control subject levels) has confirmed its possible classification performance 
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(OR=3.12, ptwo-tailed=0.0463, Figure 4A) about probability of presence of IS. The nocturnal cortisol values 
were found to be different among the 4 groups (p<0.05, Figure 4B). According to this discrimination, a 
significant difference in melatonin values at 8 a.m. among some sub-groups was revealed (p<0.05) thus 
suggesting also a disturbed diurnal melatonin profile during the acute phase of ischaemic stroke, being 
similar to that in the nocturnal melatonin (not shown). 
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Discussion 
 
In this analysis of a study cohort of young patients with ischaemic stroke we modelled the possible 
associations of the nocturnal melatonin disturbance with ischaemic stroke and we launched the 
hypothesis of its role of an eventually novel cerebro-vascular risk factor (CVRF). Notably, (i) we 
studied the differences in melatonin levels; (ii) modelled the dependence of melatonin disturbances 
upon the presence of stroke; and (iii) explored associations of presence/absence of stroke with the 
impaired nocturnal melatonin and established a new cut-off value of 51.5 pg/ml below which there might 
be a clear distinction in the continuous increase of the probability of the presence of stroke. However, 
follow-up, longitudinal studies are further needed to better clarify the eventual role of the impaired 
nocturnal melatonin (especially the deviations from its control subject’s 24-h pattern) in the IS 
pathogenesis. Thus, potentials and settings for successful prevention by add-on medications and/or melatonin 
supplementation, especially in high-risk patients, e.g., patients after transient ischaemic attack (TIA) or 
minor ischaemic stroke (MIS) [10], may be further addressed. Well-known and clinically defined 
conventional modifiable and non-modifiable risk factors for stroke are arterial hypertension, smoking, 
hyperlipidaemia, co-morbid heart diseases, diabetes, obesity, etc. Recently, however, new important factors 
emerged such as impaired nocturnal melatonin, impaired fibrinolysis, infectious agents and inflammation, 
sleep-related respiratory disorders, etc. [11-14]. Notably, as pathophysiological mechanisms, the impaired 
nocturnal melatonin may be related to suppressed natural melatonin production, impaired metabolism or 
decreased intake of melatonin-forming nutrients as well as to disturbed sleep-wake cycle (e.g., sleep-
disordered breathing) and shifted working schedules. 
The present study confirmed the patterns of a clinically established and instrumentally diagnosed 
ischaemic stroke in young patients in respect to its most frequent localizations and main focal neurological 
symptoms. Relatively early atherosclerotic patterns in our young IS patients and related pathological 
laboratory findings, if not observable but hidden, may be considered as deficiencies in the defence 
antioxidative systems associated with disturbed, decreased nocturnal melatonin. We found statistically 
significant differences in both melatonin and cortisol, but only in those measured at 3 a.m. (Table 1) and both 
maintained significant and independent role at the multivariate association with IS. It is possible that the 
impaired nocturnal melatonin in 23 of our IS patients (69.7%) be also explained by a higher extent of their 
lesions towards the intergeniculate leaflet (IGL) innervating both the suprachiasmatic nucleus and pineal 
gland as being involved mainly in the regulation of the nocturnal melatonin metabolism [15].  
It is quite probable that decreased nocturnal melatonin may show interferences with increased 
cortisol and, in the same time, it may correlate with disturbed antioxidant status [16] leading to the 
progression of atherosclerotic changes and increased risk of cerebrovascular incidents, even in younger 
patients. The established differences of nocturnal melatonin in our young patients have confirmed earlier 
results [5-6, 17]. For instance, Beloosesky et al [5] have found that the mean excretion rate of urine 
sulfatoxymelatonine (6-SMT), as a major metabolite of melatonin, had lower nocturnal (2 and 6 o’clock) 
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values on 3rd-4th days post-stroke (mainly, in extensive cortical lesions). Similarly, Fiorina and collaborators 
[6] have measured urine melatonin and also found decreased nocturnal values on 3rd day post-ischaemic 
stroke that persisted at least till the 7th day in extensive cerebral injuries. Pang and collaborators [17] have 
also reported lower nocturnal rise of plasma melatonin in acute cerebral haemorrhages. However, none of 
these studies have not even attempted to specify any possible cut-off value in such nocturnal melatonin 
decreases that may have been eventually associated with the increased probability of the presence of 
stroke. Cortisol changes were not evident in the above reports, either, but in the present studies we were able 
to find also a significant parallel nocturnal increase in the cortisol levels. It is clear that disturbances of the 
melatonin rhythm (amplitude and/or phase) during the acute phase of stroke may be also associated with 
other parallel dysregulations of the neuroendocrine (hypothalamic-pituitary-adrenal) axis that can be seen 
early in hemispheric strokes.  
Notably, it has been shown that the melatonin levels or their rhythm may recover later, in the 
reconvalescent (3-rd) period in IS patients, but our current study reported that the associations of the 
disturbances of nocturnal melatonin during the acute phase of stroke were independent from cortisol. 
Cortisol has shown also increased nocturnal levels and even higher odds ratio (OR=6.22, see Table 3), 
however, both were independently associated to IS within the multivariate backward regression model. 
Moreover, the previous multifactorial backward parametric regression analysis (Table 2) indicated that only 
the age-adjusted presence/absence of stroke (p=0.010) and gender (sex, p=0.018) were able to model the 
melatonin, but not cortisol nocturnal levels (p=0.415). 
It had been shown previously that impaired nocturnal melatonin levels might be related to worse IS 
prognosis and outcome [5-6,18]. Although we were not able to assess the prognosis after IS according to the 
decreased nocturnal melatonin, having established that decreased nocturnal melatonin (as measured during 
the acute phase of ischaemic stroke) was independently associated with the presence of stroke, we 
decided to further search for a potentially significant cut-off for this association. Thus, by logistic fitting 
and ROC analysis, we have established in younger patients and suggest a novel and well-sensitive cut-off 
value for nocturnal melatonin (51.5 pg/ml), irrespectively of age, gender and cortisol levels, to better 
discriminate and more precisely define and model correctly the patients with increased probability of 
presence of IS. We cannot assess the extent to which the decreased nocturnal melatonin that we measured 
during the acute phase has been due (as a consequence) to the index event (stroke) and/or it had been low 
(decreased) even beforehand, prior to the stroke occurrence (which, if not confirmed, cannot be excluded, 
either). In this regard, no studies were found in the literature and, although in experimental animals, a 
recent paper by Meng and collaborators [19] have shown that mainly the on-set time of melatonin nocturnal 
increase (MT-on: the time when melatonin rises to 20% of the daily maximum) increase (around 21-24 h) has 
changed from pre- to post-stroke. The authors described that middle cerebral artery occlusion caused a slight 
advance of MT-on that persisted through 4 days of monitoring, but no changes were observed for the peaked 
(amplitude) levels during the dark part of the circadian rhythm (from 22 pm to 6 am). To note, the decrease 
of nocturnal melatonin in our IS patients as compared to controls was by one-third (-21.6 pg/ml or -30.9%, 
Table 1). Assuming that our controls represent our IS patients before the occurrence of IS, this value for the 
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difference is too high to have been due only to the IS index event (post-stroke), without having been 
sufficiently lowered beforehand. Rather, the low/decreased nocturnal concentration of melatonin that we 
detected in our IS patients (i.e., during the acute phase of the ischaemic stroke) may have actually existed 
long or short before, to a large extent, as a pre-existing unknown pattern. The fact, that the pre- and post-
stroke nocturnal levels (including also the peak values at 3 a.m.) in the above experimental animals [19] 
remain relatively stable as an amplitude, may be also seen as an immediate confirmatory finding in the view 
of our current postulate about the „dormant“ („hidden“) pre-existing low nocturnal melatonin in subjects, 
eventually being at increased IS risk. This strictly indicates that decreased nocturnal melatonin levels (before 
IS) might be seen as novel, important IS risk factor and surely need further confirmation in prospective 
cohort studies. Moreover, in such populations with high background risk of IS as the Bulgarian one, a valid 
and reliable cut-off level for decreased nocturnal melatonin (at 3 a.m.) may have even more relevant and 
informative clinical applications than usually applied laboratory control subject levels. Our finding is a very 
important contribution that more precisely indicates an eventual presence of potentially ‘hidden’ but 
increased risk prevalence within a usually-defined control subject levels of nocturnal melatonin thus 
allowing better clinical application of preventive and treatment strategies in younger, but “at risk” 
populations. 
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Legends to Figures 
 
Figure 1 CONSORT flow-chart of study screening, enrolment and analysis. 
  Legend: IS, ischaemic stroke. 
 
Figure 2 Distribution of melatonin levels, measured at 3 a.m.  
  Legend: X-axis: Study participants’ anonymous identification number - black triangles 
[patients with IS (cases)], black circles [subjects without IS (controls)]; Y-axis, Melatonin 
[pg/ml]; IS, ischaemic stroke  
 
Figure 3 Models of ischaemic stroke (IS) and melatonin at 3 a.m. 
A) Probability of IS expressed as a nonlinear association along the melatonin range at 3 a.m. 
(pmodel<0.05). X-axis, Melatonin [pg/ml]; Y-axis, Probability of IS (where 0.0 = no IS; 1.0 = 
IS); Horizontal line, cut-off event probability of 0.5.  
B) ROC curve of IS versus melatonin at 3 a.m.: for a given melatonin level, the ordinate values 
indicate the corresponding true-positive rate (fraction of IS patients with this melatonin) and 
the abscissa values indicate the corresponding part of the false-positive rate (fraction of 
patients without IS with this melatonin). The inflection point of the curve was chosen as the 
optimal diagnostic value. The larger area between the ROC curve and the diagonal line 
reflects the higher degree with which the melatonin shows a predictive benefit. X-axis, 1-
Specificity; Y-axis, Sensitivity. Both estimates are expressed as a proportion of patients 
without or with IS (i.e., from 0.00 to 1.00).  
Legend: IS, ischaemic stroke.  
 
Figure 4 Analyses of  ischaemic stroke (IS) by nocturnal values of melatonin and cortisol 
A) Distribution of IS patients and controls according to the indicated cut-off level of melatonin 
(at 3 a.m.) of 51.5 pg/ml. X-axis, IS status; Y-axis, Number of subjects (where 0.0 = no IS; 
1.0 = IS); Framed numbers on white area, Number of subjects in each sub-group (column); 
Asterisk(*) indicates the significant difference at p<0.05. Legend: Blue (light) column 
[normal melatonin ≥51.5 pg/ml]; Violet (dark) column [abnormal melatonin <51.5 pg/ml].  
B) Box-plots of cortisol at 3 a.m. according to groups by combination of ischaemic status (IS 
patients, controls) and nocturnal melatonin cut-off values (normal, abnormal). X-axis, Sub-
group combinations; Y-axis, Cortisol (at 3 a.m.) values [ng/ml]. The box-plot represents the 
median (thick horizontal line within the box), interquartile range (25th-75th percentile or H-
spread, box) and min/max non-outlier (smallest/largest “whiskers”, short horizontal lines) 
values. Asterisks(*) indicate significant differences at p<0.05. Legend: IS, ischaemic stroke.  
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Table 1. Main characteristics of sex- and age-matched patients with ischaemic stroke (cases) and healthy subjects (controls) 
  
Variable [unit]* Ischemic stroke patients (cases) Healthy subjects (controls) 
Number (%) 33 (100) 33 (100) 
Gender (%) [m/f] 20 (60.6) / 13 (39.4) 20 (60.6) / 13 (39.4) 
Age [years] 58.4 ± 7.5 55.3 ± 7.4 
Melatonin (at 3 a.m.) [pg/ml] 48.1 ± 35.9 ° # 69.7 ± 44.7 
Melatonin (at 8 a.m.) [pg/ml] 23.1 ± 21.2 # 27.2 ± 20.1 
Cortisol (at 3 a.m.) [nmol/l] 297.3 ± 157.8 ° $ #  141.7 ± 120.6 
Cortisol (at 8 a.m.) [nmol/l] 483.9 ± 158.6 # 505.9 ± 154.5 
Serum creatinine [µmol/l] & 81.1 ± 27.1 $ 79.2 ± 11.7 
 
* Notes: Number or frequency (percentage) or mean ± SD, as appropriate; °p<0.05 vs healthy subjects as assessed by χ2 test 
or independent sample Student’s t-test / $non-parametric Wilcoxon's test, as appropriate. #Comparison by log-transformed 
values. & Missing data for serum creatinine in 1 patient.  
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Table 2.  Multifactorial backward parametric regression analysis for modelling of main endocrine 
parameters by presence or absence of ischaemic stroke in 66 sex- and age-matched cases and 
controls* 
       
Dependent variable Independent variable (pb-value) $ Covariates (pb-value) $ Final model (pF-value) 
Cortisol # Stroke (<0.001) Age (0.181) 
Melatonin (0.284) # 
Sex (0.322) 
Stroke (<0.001) 
Melatonin # Stroke (0.010) Sex (0.018) 
Age (0.270) 
Cortisol (0.415) # 
Stroke+Sex (0.003) 
 
* Notes: Ischaemic stroke (yes/no) and sex (male/female) are categorical variables with dichotomous 
ordinal coding (1,2); # Log-transformed values; $ Independent variables / covariates included in the initial 
models were: ischaemic stroke, sex, age, cortisol or melatonin (both at 3 o’clock), respectively; only 
variables at p<0.05 remained in the final regression models. 
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Table 3.  Logistic backward conditional regression analysis for modelling of ischaemic stroke 
(pmodel <0.001; accuracy 75.8%)* 
       
Independent variable Odds Ratio (95% CI) p 
Cortisol  # 6.22  (2.23,17.79) 0.001 
Melatonin  # 0.30  (0.12,0.76) 0.011 
 
* Notes: Ischaemic stroke (yes/no) and sex (male/female) are categorical variables with 
dichotomous ordinal coding (1,2); # Log-transformed values; $ Independent variables / covariates 
included in the initial model were: sex, age, cortisol and melatonin (both at 3 o’clock); only 
variables at p<0.05 remained in the final model. 
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Figure 3
B) ROC curve of IS
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Figure 4
B) Cortisol (3 a.m.) by IS and melatonin status
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